Literature DB >> 7849720

RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.

J E Blaugrund1, M M Johns, Y J Eby, D W Ball, S B Baylin, R H Hruban, D Sidransky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7849720     DOI： 10.1093/hmg/3.10.1895

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN： 0964-6906            Impact factor:   6.150


× No keyword cloud information.
  18 in total

1.  The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.

Authors:  J Oriola; I Halperin; F Rivera-Fillat; H Donis-Keller
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

Review 2.  Medullary thyroid cancer: monitoring and therapy.

Authors:  Douglas W Ball
Journal:  Endocrinol Metab Clin North Am       Date:  2007-09       Impact factor: 4.741

3.  RET proto-oncogene mutations and rearrangements in endocrine diseases.

Authors:  R V Lloyd
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

4.  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Authors:  Razelle Kurzrock; Steven I Sherman; Douglas W Ball; Arlene A Forastiere; Roger B Cohen; Ranee Mehra; David G Pfister; Ezra E W Cohen; Linda Janisch; Forlisa Nauling; David S Hong; Chaan S Ng; Lei Ye; Robert F Gagel; John Frye; Thomas Müller; Mark J Ratain; Ravi Salgia
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 5.  Multiple endocrine neoplasia type 2.

Authors:  Mariola Peczkowska; Andrzej Januszewicz
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 6.  Personalizing therapy in advanced non-small cell lung cancer.

Authors:  Liza C Villaruz; Timothy F Burns; Vasilis S Ramfidis; Mark A Socinski
Journal:  Semin Respir Crit Care Med       Date:  2013-11-20       Impact factor: 3.119

Review 7.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

8.  DNA copy number changes in thyroid carcinoma.

Authors:  S Hemmer; V M Wasenius; S Knuutila; K Franssila; H Joensuu
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 9.  State-of-the-Art Strategies for Targeting RET-Dependent Cancers.

Authors:  Vivek Subbiah; Dong Yang; Vamsidhar Velcheti; Alexander Drilon; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

Review 10.  Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Authors:  Vinayak Palve; Yi Liao; Lily L Remsing Rix; Uwe Rix
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.